Adaptive Biotechnologies to Report Third Quarter Financial Results on November 12, 2019

NEXT STORY
Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update
PREV STORY
CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Taconic Biosciences is First and Only Animal Vendor to Announce All Commercial Mouse Colonies Free of New Pathogen

author_avatar
NASDAQ Market News

Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseases

author_avatar
NASDAQ Market News

Immutep Quarterly Activities Report

author_avatar
NASDAQ Market News